Quantification confirmed that the optimally designed Her2/VEGFR2/CD3 (SO) significantly increased T-cell recruitment in the tumor microenvironment compared with saline and bsAbs, but this significance was not found between tsAb and the bsAbs combination (Figure 3G), which suggested that the tumor suppression with tsAb treatment could be in part due to the synergistic T-cell-redirecting activation in response to dual antigen expression on tumors. This evidence concerns the gene ERBB2 and neoplasm.